Voglibose is an α-glucosidase inhibitor discovered in 1981 in Japan that is used to treat postprandial hyperglycemia by reversibly inhibiting the intestinal enzyme α-glucosidase and preventing increases in blood glucose levels after meals. It was commercially available starting in 1995 and manufacturing information such as processes, materials, and market players are available from the source cited.

1. Voglibose
Presentation by
Primary Information Services
www.primaryinfo.com
mailto:primaryinfo@gmail.com

2. Voglibose is categorized as an α glucosidase
inhibitors, it was discovered in Japan in 1981 when
it was isolated from the culture media producing
Streptomyces hygroscopicity var.
• limonons and was commercially available since
1995 for the treatment of postprandial
hyperglycemia.
• It exerts an anti-hypoglycemic action from a
reversible inhibition of the membrane-bound
intestinal enzyme α glycosidase hydrolyze and
prevents the increase in blood glucose level
post-meal.

4. Database Offer:
Manufacturing Process
Route of Synthesis
Process Flow Diagram
Input and output and mass Balance
Pollution load
Solvent Balance of Voglibose
Raw Materials
Patents, COA, MSDS, SDS

7. Market Players:
Eris
Life Care
Sarian
Pfizer Limited
Blue Cross
AS Pharma
Neelkanth Healthcare (P)Ltd
Strides
Three Dots Lifesciences
Nexus Biotech
Panacea Biotec Ltd
Unichem